May 14th 2024
Dynavax is currently reviewing FDA feedback and strategizing a meeting to discuss their HEPLISAV-B 4-dose regimen for hemodialysis patients, determining the path forward toward approval.
Reactivation of Hepatitis B Associated With Immunosuppressive Medications
May 30th 2015In patients with chronic HBV, the immune system may have very low levels of the virus. When reactivation occurs due to immunosuppression, these viruses begin to replicate again. Common symptoms of this event include inflammation of the liver and elevations of liver enzyme levels in the blood. In some cases, bilirubin levels may rise in response to reactivation of infection.
Read More
Tenofovir Plus Interferon Improves Antigen Clearance in Chronic Hepatitis B
December 13th 2014Treatment with a combination of tenofovir and pegylated interferon yielded higher rates of hepatitis B surface antigen (HBsAg) loss than when either drug was used singly. Further, with longer therapy duration improved results.
Read More
Triple Therapy for Hepatitis C Infection: Bacterial Infection Risk Rises, Changes
December 1st 2014Patients who have HCV infection are at high risk for arthralgia, myalgias, pruritus, neuropathy, and decompensated livers. Until recently the sole available treatment was interferon. After the US Food and Drug Administration (FDA) approved ribavirin, patients who took ribavirin plus interferon responded better. Now, the FDA has approved a small selection of oral antivirals to treat hepatitis C.
Read More
Recommendations to Improve Liver Health in Hepatitis B, Hepatitis C Patients
September 10th 2014Although it is widely understood that hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading causes of liver cirrhosis and liver cancer, an alarming number of HBV and HCV carriers have unhealthy habits that result in poor liver health.
Read More
Serious Liver Disease Rates Higher Among Coinfected Patients
June 19th 2014Study results show hepatic decompensation is more common in people who have both HIV and hepatitis C virus (HCV) compared to those infected only with HCV, an indication that early HCV treatment among coinfected patients is needed.
Read More